Quinupristin/dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitis
- PMID: 10381105
- DOI: 10.1093/jac/43.1.87
Quinupristin/dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitis
Abstract
The inflammatory response following initiation of antibiotic therapy and parameters of neuronal damage were compared during intravenous treatment with quinupristin/dalfopristin (100 mg/kg as either a short or a continuous infusion) and ceftriaxone (10 mg/kg/h) in a rabbit model of Streptococcus pneumoniae meningitis. With both modes of administration, quinupristin/dalfopristin was less bactericidal than ceftriaxone. However, the concentration of proinflammatory cell wall components (lipoteichoic acid (LTA) and teichoic acid (TA)) and the activity of tumour necrosis factor (TNF) in cerebrospinal fluid (CSF) were significantly lower in the two quinupristin/dalfopristin groups than in ceftriaxone-treated rabbits. The median LTA/TA concentrations (25th/75th percentiles) were as follows: (i) 14 h after infection: 133 (72/155) ng/mL for continuous infusion of quinupristin/dalfopristin and 193 (91/308) ng/mL for short duration infusion, compared with 455 (274/2042) ng/mL for ceftriaxone (P = 0.002 and 0.02 respectively); (ii) 17 h after infection: 116 (60/368) ng/mL for continuous infusion of quinupristin/dalfopristin and 117 (41/247) ng/mL for short duration infusion, compared with 694 (156/2173) ng/mL for ceftriaxone (P = 0.04 and 0.03 respectively). Fourteen hours after infection the median TNF activity (25th/75th percentiles) was 0.2 (0.1/1.9) U/mL for continuous infusion of quinupristin/dalfopristin and 0.1 (0.01/3.5) U/mL for short duration infusion, compared with 30 (4.6/180) U/mL for ceftriaxone (P = 0.02 for each comparison); 17 h after infection the TNF activity was 2.8 (0.2/11) U/mL (continuous infusion of quinupristin/dalfopristin) and 0.1 (0.04/6.1) U/mL (short duration infusion), compared with 48.6 (18/169) U/mL for ceftriaxone (P = 0.002 and 0.001). The concentration of neuron-specific enolase (NSE) 24 h after infection was significantly lower in animals treated with quinupristin/dalfopristin: 4.6 (3.3/5.7) microg/L (continuous infusion) and 3.6 (2.9/4.7) microg/L (short duration infusion) than in those treated with ceftriaxone (17.7 (8.8/78.2) microg/L) (P = 0.03 and 0.009 respectively). In conclusion, antibiotic treatment with quinupristin/dalfopristin attenuated the inflammatory response within the subarachnoid space after initiation of antibiotic therapy. The concentration of NSE in the CSF, taken as a measure of neuronal damage, was lower in quinupristin/dalfopristin-treated rabbits than in ceftriaxone-treated rabbits.
Similar articles
-
Differential release of lipoteichoic and teichoic acids from Streptococcus pneumoniae as a result of exposure to beta-lactam antibiotics, rifamycins, trovafloxacin, and quinupristin-dalfopristin.Antimicrob Agents Chemother. 1998 Feb;42(2):277-81. doi: 10.1128/AAC.42.2.277. Antimicrob Agents Chemother. 1998. PMID: 9527772 Free PMC article.
-
Release of teichoic and lipoteichoic acids from 30 different strains of Streptococcus pneumoniae during exposure to ceftriaxone, meropenem, quinupristin/dalfopristin, rifampicin and trovafloxacin.Infection. 2000 Jan-Feb;28(1):13-20. doi: 10.1007/s150100050004. Infection. 2000. PMID: 10697785
-
Lower lipoteichoic and teichoic acid CSF concentrations during treatment of pneumococcal meningitis with non-bacteriolytic antibiotics than with ceftriaxone.Scand J Infect Dis. 1999;31(4):367-70. doi: 10.1080/00365549950163806. Scand J Infect Dis. 1999. PMID: 10528875
-
Clinical pharmacokinetics of quinupristin/dalfopristin.Clin Pharmacokinet. 2004;43(4):239-52. doi: 10.2165/00003088-200443040-00003. Clin Pharmacokinet. 2004. PMID: 15005638 Review.
-
A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas.J Antimicrob Chemother. 1997 May;39 Suppl A:59-62. doi: 10.1093/jac/39.suppl_1.59. J Antimicrob Chemother. 1997. PMID: 9511064 Review.
Cited by
-
Inadequate Cerebrospinal Fluid Concentrations of Available Salvage Agents Further Impedes the Optimal Treatment of Multidrug-Resistant Enterococcus faecium Meningitis and Bacteremia.Infect Dis Rep. 2021 Sep 8;13(3):843-854. doi: 10.3390/idr13030076. Infect Dis Rep. 2021. PMID: 34563001 Free PMC article.
-
A Review: Antimicrobial Therapy for Human Pythiosis.Antibiotics (Basel). 2022 Mar 26;11(4):450. doi: 10.3390/antibiotics11040450. Antibiotics (Basel). 2022. PMID: 35453202 Free PMC article. Review.
-
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008. Drugs. 1999. PMID: 10651391 Review.
-
Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.Antimicrob Agents Chemother. 2001 Jul;45(7):2169-72. doi: 10.1128/AAC.45.7.2169-2172.2001. Antimicrob Agents Chemother. 2001. PMID: 11408247 Free PMC article.
-
Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis.Infect Immun. 2001 Nov;69(11):6881-6. doi: 10.1128/IAI.69.11.6881-6886.2001. Infect Immun. 2001. PMID: 11598062 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical